12:00 AM
Oct 25, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Antova: Halted Phase II testing

Biogen Inc. (BGEN), Cambridge, Mass.
Product: Antova
Business: Autoimmune/Inflammation
Therapeutic category: Antibody, Immune suppression
Target: CD40 ligand
Description: Humanized anti-CD40 ligand monoclonal...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >